These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 24815094

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
    Geller DE, Nasr SZ, Piggott S, He E, Angyalosi G, Higgins M.
    Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
    [Abstract] [Full Text] [Related]

  • 3. Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection.
    Greenwood J, Schwarz C, Sommerwerck U, Nash EF, Tamm M, Cao W, Mastoridis P, Debonnett L, Hamed K.
    Ther Adv Respir Dis; 2017 Jul; 11(7):249-260. PubMed ID: 28614995
    [Abstract] [Full Text] [Related]

  • 4. Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study.
    Blasi F, Carnovale V, Cimino G, Lucidi V, Salvatore D, Messore B, Bartezaghi M, Muscianisi E, Porpiglia PA, FREE study group.
    Respir Med; 2018 May; 138():88-94. PubMed ID: 29724399
    [Abstract] [Full Text] [Related]

  • 5. Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis.
    Panguluri S, Gunda P, Debonnett L, Hamed K.
    Clin Drug Investig; 2017 Aug; 37(8):795-805. PubMed ID: 28643178
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C.
    Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.
    Somayaji R, Parkins MD.
    Ther Deliv; 2015 Feb; 6(2):121-37. PubMed ID: 25690082
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis.
    Regnault A, Balp MM, Kulich K, Viala-Danten M.
    J Cyst Fibros; 2012 Dec; 11(6):494-501. PubMed ID: 22583743
    [Abstract] [Full Text] [Related]

  • 15. A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.
    Littlewood KJ, Higashi K, Jansen JP, Capkun-Niggli G, Balp MM, Doering G, Tiddens HA, Angyalosi G.
    J Cyst Fibros; 2012 Sep; 11(5):419-26. PubMed ID: 22717535
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of Inhaled Antibiotics for the Treatment of Chronic Pseudomonas aeruginosa Lung Infection in Patients With Cystic Fibrosis: Systematic Literature Review and Network Meta-analysis.
    Elborn JS, Vataire AL, Fukushima A, Aballea S, Khemiri A, Moore C, Medic G, Hemels ME.
    Clin Ther; 2016 Oct; 38(10):2204-2226. PubMed ID: 27692977
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.